Glenmede Trust’s ChemoCentryx, Inc. CCXI Stock Holding History

Glenmede Trust’s Portfolio CCXI Stock Details CCXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-4,806	Closed	-$246K	–	1327
2021 Q1	$246K	Buy	4,806 +59	+1%	+$3.55K	﹤0.01%	1024
2020 Q4	$293K	Buy	4,747 +2,225	+88%	+$127K	﹤0.01%	969
2020 Q3	$138K	Buy	2,522 +2,485	+6,716%	+$134K	﹤0.01%	1095
2020 Q2	$2K	Buy	+37	New	+$2.01K	﹤0.01%	2288

Other funds holding CCXI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Glenmede Trust's CCXI Position: Q2 2021 in Review

Glenmede Trust sold out of ChemoCentryx, Inc. (CCXI) in Q2 2021, closing a stake of 4,806 shares — an estimated $246K sold.

Glenmede Trust first reported a position in CCXI in Q2 2020 and held it in 4 quarters. The position peaked at $293K in Q4 2020. 146 funds tracked by Wall St. Rank hold CCXI as of Q2 2021.

Glenmede Trust reported no remaining ChemoCentryx, Inc. position as of Q2 2021 after selling out during the quarter.
Glenmede Trust sold 4,806 ChemoCentryx, Inc. shares in Q2 2021, an estimated $246K.
Glenmede Trust first reported a position in ChemoCentryx, Inc. in Q2 2020 and held it in 4 quarters.
Glenmede Trust's ChemoCentryx, Inc. position peaked at $293K in Q4 2020.
146 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q2 2021.

Based on Glenmede Trust's 13F filing for Q2 2021, filed 16 Aug 2021.